Summary
Mutation of the p53 tumour suppressor gene often leads to the accumulation of mutant p53 protein in tumour cells. Many cancer patients develop antibodies that recognize the overexpressed p53 protein. The presence of these antibodies is, in some tumour types, associated with poor prognosis. Gastric cancer is a highly prevalent disease associated with a high rate of mortality, there is a need for improved clinical and biological markers for disease behaviour. To investigate the clinical relevance of serum anti-p53 antibodies in patients with gastric adenocarcinoma, we have examined the sera of 501 gastric cancer patients for the presence of serum antibodies against the p53 protein. By immunoblotting analysis using a cell lysate containing overexpressed p53 protein as well as affinity-purified recombinant p53 protein as antigens, we have detected anti-p53 antibodies in 11.2% (61 of 501) of gastric cancer patients, but in none of 46 cancer-free individuals. The presence of anti-p53 antibodies was tightly associated with tumours of higher nuclear grade and lymph node metastasis, and a negative association was found between the presence of anti-p53 antibodies and survival. These results suggest that a preoperative test of serum anti-p53 antibodies in gastric cancer patients can be useful to identify subset of patients who may need gastrectomy with lymph node dissection and post-operative adjuvant therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A. & Bunting, P. S. (1994). Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480–487.
Ben-Mahrez, K., Sorokine, I., Thierry, D., Kawasumi, T., Ishii, S., Salmon, R. & Kohiyama, M. (1990). Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46: 35–38.
Bourhis, J., Lubin, R., Roche, B., Koscielny, S., Bosq, J., Dubois, I., Talbot, M., Marandas, P., Schwaab, G., Wibault, P., Luboinski, B., Eschwege, F. & Soussi, T. (1996). Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 1228–1233.
Caron de Fromentel, C., May-Levine, F., Mouriesse, H., Lemerle, J., Chandresekaran, K. & May, P. (1987). Presence of circulating antibodies against the cellular protein p53 in a notable proportion of children with B cell lymphoma. Int J Cancer 39: 185–189.
Chen, J-Y, Funk, W. D., Wright, W. E., Shay, J. W. & Minna, J. D. (1993). Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159–2166.
Crawford, L., Pim, D. & Bulbrook, R. (1982). Detection of antibodies against the cellular protein p53 in sera from patient with breast cancer. Int J Cancer 30: 403–408.
Davidoff, A., Humphrey, P., Iglehart, J. & Marks, J. (1991). Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010.
Davidoff, A. M., Iglehart, J. D. & Marks, J. R. (1992). Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439–3442.
Dixon, W. J. (1988). BMDP Statistical Software Manual. University of California Press: Berkeley
Gabbert, H. E., Muller, W., Schneiders, A., Meier, S. & Hommel, G. (1995). The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76: 720–726.
Kakeji, Y., Korenaga, D., Tsujitani, S., Baba, H., Anai, H., Maehara, Y. & Sugimachi, K. (1993). Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67: 589–593.
Kern, S., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W. & Vogelstein, B. (1992). Oncgenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827–830.
Lane, D. & Benchimol, S. (1990). p53: oncogene or anti-oncogene? Genes Dev 4: 1–8.
Levine, A., Momand, J. & Finlay, C. (1991). The p53 tumour suppressor gene. Nature 351: 453–455.
Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron de Fromental, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Le Duc, A., Peyrat, J. P., Janin, N., Bressac, B. & Soussi, T. (1993). Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872–5876.
Lubin, R., Zalcman, G., Bouchet, L., Tredaniel, J., Legros, Y., Cazals, D., Hirsch, A. & Soussi, T. (1995). Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701–702.
Motojima, K., Furui, J., Kohara, N., Ito, T. & Kanematsu, T. (1994). Expression of p53 protein in gastric carcinoma is not independently prognostic. Surgery 116: 890–895.
Peyrat, J. P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J. & Soussi, T. (1995). Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621–623.
Rosenfeld, M. R., Malats, N., Schramm, L., Graus, F., Cardenal, F., Vinolas, N., Rosell, R., Tora, M., Real, F. X., Posner, J. B. & Dalmau, J. (1997). Aerum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 89: 381–385.
Sang, B. C., Chen, J-Y, Minna, J. D. & Barbosa, M. S. (1994). Distinct regions of p53 have a differential role in transcriptional activation and repression functions. Oncogene 9: 853–859.
Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F. & Soussi, T. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380–6384.
Sorokine, I., Ben-Mahrez, K., Bracone, A., Thierry, D., Ishii, S., Imamoto, F. & Kohiyama, M. (1991). Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 47: 665–669.
Unger, T., Nau, M., Segal, S. & Minna, J. (1992). p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11: 1383–1390.
Wild, C. P., Ridanpaa, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen, K. & and Vainio, H. (1995). p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. Int J Cancer 64: 176–181.
Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gardar, A. F. & Carbone, D. P. (1992). Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168–4174.
Wu, C-W, Hsieh, M-C, Lo, S-S, Lui, W-Y & P’eng, F-K (1996a). Results of curative gastrectomy for carcinoma of the distal third of the stomach. J Am Coll Surg 183: 201–207.
Wu, C-W, Hsieh, M-C, Lo, S-S, Tsay, S-H, Lui, W-Y & P’eng, F-K (1996b). Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Gut 38: 525–527.
Wu, C-W, Hsieh, M-C, Lo, S-S, Tsay, S-H, Lui, W-Y & P’eng, F-K (1996c). Lymph node metastasis from carcinoma of the distal one-third of the stomach. Cancer 73: 2059–2064.
Wu, C-W, Hsieh, M-J, Lo, S-S, Tsay, S-H, Li, AF-Y, Lui, W-Y & P’eng, F-K (1997). Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci 42: 1265–1269.
Wurl, P., Weigmann, F., Meye, A., Fiittkau, M., Rose, U., Berger, D., Rath, F-W, Dralle, H. & Taubert, H. (1997). Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroentrol 32: 1147–1151.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wu, CW., Lin, YY., Chen, GD. et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 80, 483–488 (1999). https://doi.org/10.1038/sj.bjc.6690382
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690382
Keywords
This article is cited by
-
Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery
Surgery Today (2020)
-
Unusually high levels of serum p53 antibody in recurrent gastric cancer
Clinical Journal of Gastroenterology (2017)
-
Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients
Gastric Cancer (2005)